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Interventional Radiology (IR) is occupying an increasingly prominent role in the care of patients with cancer, with involvement
from initial diagnosis, right through to minimally invasive treatment of the malignancy and its complications. Adequate diagnostic
samples can be obtained under image guidance by percutaneous biopsy and needle aspiration in an accurate and minimally
invasive manner. IR techniques may be used to place central venous access devices with well-established safety and eﬃcacy.
Therapeutic applications of IR in the oncology patient include local tumour treatments such as transarterial chemo-embolisation
and radiofrequency ablation, as well as management of complications of malignancy such as pain, organ obstruction, and venous
thrombosis.
1. Introduction
Management of malignancy is now in the domain of the
multi-disciplinary team and Interventional Radiology (IR)
is occupying a prominent role in this environment [1, 2].
IR input begins with establishing the initial diagnosis of
cancer, and involvement now extends to minimally invasive
treatment of malignancy, often in combination with other
modalities. IR has also assumed an important place in the
management of the complications of malignancy, which may
result frommalignancy itself or secondary to treatment. This
paper provides an updated overview of the role of IR in the
management of the oncology patient.
2. Interventional Radiology in the
Diagnosis of Cancer
Appropriate treatment of malignancy is dependent on a
timely definitive diagnosis and on accurate staging of dis-
ease. While non-invasive imaging techniques have improved
assessment and staging for cancer, histologic confirmation
remains the gold standard for definitive diagnosis of many
tumours. Biopsies to establish histological diagnosis are
increasingly performed using minimally invasive techniques
by interventional radiologists [3]. The direct visualisation
enabled by image guidance during biopsy permits safe
passage of a needle into an organ or mass, improving
eﬃcacy and minimising trauma to surrounding structures
(Figure 1). These minimally invasive techniques are applica-
ble to a wide range of biopsy sites and, inmost organ systems,
have been demonstrated to be highly accurate with a low
complication rate [3]. In biopsy planning, modern cross-
sectional imaging techniques help define lesion location,
accessibility, and suitability for biopsy and aid in ensuring
the correct lesion is sampled in the context of multiple
lesions. In selected cases where lesions are present in more
than one organ, percutaneous biopsy may be used to
concurrently confirm histological diagnosis and establish
oncological staging by sampling the lesion suspicious for
metastasis [4] (Figure 2). With improving histological and
cytological techniques, particularly in immunohistochemical
analysis, histological and possibly molecular examination
may determine with more certainty the probable under-
lying primary tumour site and can predict sensitivity to
chemotheraputic drugs in some cases [5]. In cases where
surgical biopsy remains the preferred diagnostic approach,
pre-operative tumour localisation can be performed with
image guidance in many situations; an example of this is
wire-localisation prior to excisional breast biopsy [6] and
in the chest to guide video-assisted thorascopic surgery
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Figure 1: 64-year-old man with lung lesion: (a) CT scan of chest in supine position shows left-sided lung lesion. (b) A 19-gauge needle has
been positioned within the lesion under CT guidance and core biopsy is then performed using coaxial technique.
(VATS) for removal of lung nodules that would otherwise
require open thoracotomy [7]. Increasingly, percutaneous
biopsy is utilised for microbiological diagnosis of lesions
suspicious for opportunistic infections (particularly fungal)
in oncology patients with febrile neutropenia [8]. Choice
of image guidance modality is multifactorial and there are
many available options. Ultrasound oﬀers the benefit of real-
time imaging allowing accurate monitoring of the needle
trajectory through tissues en route to the target lesion, with
the dual advantage of avoiding patient and staﬀ exposure
to ionising radiation during the biopsy [9]. When lesions
are visible by ultrasound, with suitable equipment and
appropriate operator experience, this modality can provide
equivalent or superior guidance to CT at time of biopsy
[9]. CT guidance oﬀers enhanced anatomical detailing and
delineation with more precise needle localisation when
compared to ultrasound [9]. Complications, if any, are easily
recognised on CT scan. It finds particular utility in thoracic,
pelvic, and retroperitoneal biopsies which are frequently
diﬃcult to perform under ultrasound guidance [8]. The
main disadvantage is exposure to ionising radiation; both
patient and, to a lesser extent, staﬀ are exposed to this at
time of biopsy, and the extent of such radiation exposure
is related to the total scan time, scan parameters such
as peak tube kilovoltage (kVp) and milliamperage (mA),
the body part imaged, and the size of the patient. CT
fluoroscopy is an additional tool which allows near real-
time imaging of needle trajectory, which when appropriately
used will shorten procedure duration [10]. Fluoroscopic
images are acquired at a lower milliamperage (mA) than
standard CT guidance permitting lower radiation dose to the
patient, though the radiation dose to physician and assisting
staﬀ is increased [11]. Use of recently available modality
fusion image guidance systems during ultrasound-guided
procedures, where there is real-time projection of a needle
or probe onto a pre-existing CT or MRI image, improves
accuracy of needle placement while reducing radiation
exposure to patient, physician, and staﬀ [12].
3. Interventional Radiology in the
Treatment of Cancer
3.1. Central Venous Access. An integral part of care of the
cancer patient is intermediate and longer-term vascular
access as a means of medication, chemotherapy, or parenteral
nutrition administration, as well as allowing repeated blood
sampling without need for venepuncture. On an annual basis
in the UK, over 200,000 central access devices are inserted,
many in oncology patients and while previously inserted
by anaesthetists and surgeons, IR techniques are now
commonly employed to site these devices [13]. Image-guided
percutaneous central venous access involves placement of a
catheter with its tip at the cavoatrial region or right atrium
with assistance of real-time imaging, usually fluoroscopy
or ultrasonography [14]. Intraprocedural complications of
central access catheter insertion are typically related to injury
to surrounding structures or catheter malposition, and thus
occur less frequently when performed under image guidance
than with blind technique guided by external landmarks [14–
16]. The right internal jugular vein is the most commonly
used central access route, but image guidance is particularly
useful to map alternative access routes in diﬃcult cases
[17]. The longer-term complications of central access devices
include thrombosis and infection and rates of these are
unaﬀected by insertion technique. Patients with cancer have
a 4- to 6- fold increased risk of thrombosis compared with
the general population, a risk which is further increased
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Figure 2: 72-year-old-man with right lung mass and adrenal mass: biopsy of adrenal mass facilitates histological diagnosis and definitive
staging in one procedure. (a) CT scan shows right upper lobe spiculated nodule. There is severe background emphysema, which increases the
risk associated with percutaneous lung biopsy. (b) CT scan of the upper abdomen shows a left adrenal mass (arrow), suspicious for metastatic
disease. (c) Percutaneous biopsy of left adrenal gland in left lateral decubitus position achieves histological diagnosis and confirms advanced
staging. The risk of pneumothorax is avoided.
by placement of a CVC [18, 19]. Clinically overt CVC-
related deep venous thrombosis (DVT) in cancer patients
can have an incidence as high as 28% [20, 21]. In cancer
patients with CVC-related DVT, the incidence of clinically
overt pulmonary embolism (PE) varies between 15% and
25% [20, 21]. The incidence of thromboembolism has
been reported to increase with large multilumen catheters,
those in left sided veins, and those inserted into patients
with inherited and acquired prothrombotic tendencies [22].
Thrombotic prophylaxis with low dose warfarin and heparin
has not been shown to reduce the incidence of thrombosis
in patients with central access catheters, so anticoagulation
prophylaxis is not currently recommended [23, 24]. No
uniformly accepted method of therapeutic anti-coagulation
or duration of treatment exists, with most patients treated
with anticoagulation therapy for 6 weeks to a year, dependent
on the extent of the thrombus, response to initial therapy,
and whether thrombophilic factors persist [23].
3.2. Arterial Embolisation Techniques. Minimally invasive
image-guided cancer treatments as an adjunct or alternative
to surgery are increasingly being used in the manage-
ment of malignancy [25, 26]. Delineation of the arterial
supply of a solid tumour by contrast enhanced CT or
MRI facilitates devascularisation of neoplastic tissue by
transcatheter embolisation [27]. Bland mechanical occlusion
can be achieved by Gelfoam (Upjohn, Kalamazoo, MI),
polyvinyl alcohol, blood clots, Amplatzer occlusion devices,
coils and embospheres (Biosphere medical, Rockland, MA)
introduced into the tumour bed and lodged in the feed-
ing vessel following fluoroscopic guided selective arterial
catheterisation by IR [28–30]. This technique can be used
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Figure 3: 68-year-old man with hepatocellular carcinoma in segment VI of liver: (a) selective cannulation of right hepatic artery performed
demonstrating tumour blush pre-embolisation with (b) absence of this tumour blush post infusion of 40mg of doxorubicin on 300–500 µm
beads into this branch.
alone as the primary modality of treatment, where inter-
ruption of the aﬀerent blood supply to the tumour induces
hypoxia and inhibits tumour growth, or in conjunction with
ablative treatments or conventional surgery [28]. In the case
of hepatic neoplasms, absence of arterial phase enhancement
of a previously hypervascular lesion when reimaged 4 to 6
weeks following treatment suggests success [25, 31]. Arterial
embolisation also has a role prior to surgical resection of
hypervascular tumours in an eﬀort to reduce operative blood
losses. In a palliative setting, embolisation may be used to
reduce tumour burden and aid symptomatic relief [32]. In
acute haemorrhagic complications of malignancy, such as
massive haemoptysis, haematemesis or pleural or peritoneal
haemorrhage, IR embolisation of the bleeding vessel has
therapeutic applications also [32].
Transarterial chemoembolisation (TACE) is a modifi-
cation of the above technique which is usually applied
to hepatic tumours. Following selective hepatic artery
catheterisation, a single or combination chemotherapy agent
combined with a delivery agent, usually ethiodized oil
(Ethiodol, Savage, Melville, NY), is directly infused along
with an embolic agent that occludes the flow through the
catheterised artery [28] (Figure 3). Hepatic tumours rely on
the hepatic artery for the majority of their blood supply, as
demonstrated by a tenfold greater uptake of radioisotope,
in the form of radio-labelled albumen, following hepatic
artery infusion when compared to portal vein infusion
[33]. The advantage of TACE over systemic chemotherapy
is that delivery of the chemotherapeutic agent is targeted
at the lesion allowing a higher local concentration of the
agent and lower systemic doses. Embolisation of the artery
increases the dwell time of the chemotherapeutic agent.
Chemoembolisation has the advantage of being repeatable
and treatment may involve a number of sessions until the
entire tumour bed is devascularised [8]. The liver tolerates
this procedure because of its dual blood supply and, to avoid
hepatic necrosis, chemoembolisation should be performed
with caution in the absence of portal vein patency or a
suﬃcient alternative blood supply to the liver [34]. Drug-
eluting beads (DEB) comprise particles of variable size which
bind and elute doxorubicin in a predictable manner. They
may be used in the place of standard chemotherapeutic
agent infusion during the TACE procedure in patients with
hepatocellular carcinoma and have shown promising results
to date, making them likely to be of therapeutic benefit in the
future [35].
Radioembolisation, a novel form of liver-directed
brachytherapy, is another modality with potential for
focussed treatment of hepatic malignant lesions [36, 37].
Selective catheter placement allows introduction of beta-
radiation emitting radioisotopes directly into the tumour
mass by means of microspheres (glass, albumen, or resin)
[38]. Depending on the nature of the tumour, various
radionuclides are used, including Yttrium 90, rhenium, and
holmium [36, 39]. Beta radiation has a very low penetration
(approximately 2.5mm in human tissues), thus its necrosing
eﬀects are localised [40]. The concurrent emission of a small
amount of gamma radiation, which is capable of penetrating
the body tissues, allows detection of the radiolabelled
particles by a gamma camera and appropriate localisation of
isotope can be confirmed. Accurate transcatheter delivery of
radioisotopes has been shown to be safe, with eﬃcacy con-
firmed on preliminary results [41, 42]. Radioembolisation
has been reported to produce a meaningful response and
disease stabilisation in patients with advanced unresectable
liver metastases, and may be potentially very useful in
patients with chemorefractory metastatic colorectal cancer
[43]. Technically radioembolisation is more diﬃcult than
chemoembolisation, with potential for inadvertent nontarget
embolisation of other organs, particularly the stomach, small
bowel, and gall-bladder, causing slow-healing gastrointesti-
nal ulcers or cholecystitis respectively [40]. Other potential
adverse eﬀects include pneumonitis and radioembolisation-
induced liver disease, therefore use should be restricted to
patients with a serum bilirubin of less than 2mg/dL and to
patients without significant hepatopulmonary shunting [35].
3.3. Gene Therapy. Advances in molecular oncology and
tumour immunology have facilitated the development of
gene therapy in the treatment of malignancy [44]. Strategies
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employed include stimulation of the immune response to the
tumour, reduction of oncogenic expression, restoration of
tumour suppressor gene function, alteration of susceptibility
of proliferating tumour cells to chemotherapeutics, and
modulation of angiogenesis [44, 45]. In an IR technique
similar to that used in chemoembolisation, genetic agents
may be administered directly into the tumour mass by
selective arterial injection, after which the vessel is embolised
thus limiting adverse eﬀects and prolonging agent dwell time
which is believed to improve genetic transfer rate [46]. As
DNA has a limited ability to cross cell membranes, vector
agents are used to optimise transfection rates and achieve
adequate expression of the therapeutic molecule within a
cell [46]. Common vectors include plasmids and phos-
pholipid agents, which have short-lived eﬀects, and viruses
(retroviruses, adenoviruses, EBV), which have demonstrated
more lasting genetic expression. Clinical experience with
these therapies to date is limited with studies limited to
small patient cohorts who have failed conventional therapies.
However, results in treatment of hepatic neoplasms and their
metastases appear promising [47, 48].
3.4. Ablative Techniques. Local tumour ablation is an alter-
native method of achieving tumour control in those patients
with early stage malignant disease, particularly in the liver,
who are not candidates for resection. IR mediated tumour
ablation induces tumour necrosis by the application of
energy and modalities employed include radiofrequency
(RF), laser, microwave, ultrasound and cryotherapy [49].
Radiofrequency ablation (RFA) involves administration of
electromagnetic energy in the radiofrequency range to a
tumour by means of a locally placed electrode connected
in a closed loop circuit to a monopolar or bipolar energy
source [50]. Tissues immediately surrounding the electrode
tip are heated to temperatures in excess of 60 degrees Celsius
with consequent thermal damage to the surrounding tissues
and cell death [50]. RFA has been demonstrated to be safe
with a mortality rate of 0.3% and a major complication rate
of 2.2% [51], and has gained acceptance as a method of
managing hepatic and lung malignant disease, with eﬃcacy
also described in the treatment of adrenal, renal, and skeletal
lesions [25, 52, 53]. While RFA is the most commonly
used ablative means, other modalities are finding increasing
clinical use. Cryoablation results in cell death through the
application of subfreezing temperatures, achieved by use
of argon gas under high pressure [54]. Alternating cycles
of freezing and thawing results in cell death due to the
associated mechanical stresses upon cell membranes with
phase change and ice formation and microvascular throm-
bosis induces tissue ischaemia which limits bleeding [55].
The application of electromagnetic energy in the microwave
range (at least 900MHz) agitates water molecules in targeted
tissues, resulting in frictional heat and cell death via coagula-
tion necrosis [56]. Though direct comparison of modalities
is diﬃcult, as a therapeutic tool, microwave ablation has
been shown comparable in eﬃcacy to RFA, particularly for
the treatment of hepatocellular carcinoma [57], however,
RFA achieves a lower local recurrence rate, higher survival
rate, and extensive necrosis after only a few treatment
sessions [58]. Potential added benefits of microwave ablation
over RFA include larger tumour ablation volumes, optimal
heating of cystic masses, and less procedural pain [59]. The
involutional changes that occur following necrosis should be
monitored by serial imaging following ablation, with specific
postablation CT and MR imaging protocols being developed
at many institutions in an eﬀort to confirm completeness of
ablation and to detect residual or recurrent disease [8, 60].
4. Interventional Radiology in the
Management of the Complications of Cancer
Malignancy can induce dysfunction of many organs and
bodily systems. Though debilitating, a significant portion
of these complications are reversible, many by minimally
invasive IR methods. Such treatment can relieve symptoms,
alleviate pain, and improve operability of patients, thus
having a significant positive impact on quality of life.
4.1. Biliary Obstruction. The majority of patients presenting
with malignant biliary obstruction have an underlying
pancreatic neoplasm extrinsically compressing the distal
bile duct and can be treated by endoscopic means [61].
Metastatic disease at the hepatic hilar nodes or in the
peripancreatic nodes may cause obstructive jaundice from
extrinsic pressure on the proximal portions of the biliary
tree and may require percutaneous intervention if less
invasive endoscopic means fails to achieve adequate biliary
decompression. Contrast injection into an intra-hepatic
bile duct at percutaneous transhepatic cholangiography will
delineate the anatomy of the biliary tree, determining the
location of obstruction, and helping to guide intervention
[62]. Percutaneous transhepatic biliary drainage (PBD) is an
eﬀective method for the primary or palliative management of
many biliary abnormalities demonstrated with cholangiog-
raphy. This procedure involves selective cannulation of the
biliary tree with catheter manipulation, then placement of
a catheter or stent to facilitate internal or external drainage
of biliary flow and so allow decompression of the biliary
system [8]. Metal stents have a six-month patency rate of
50% and are thus almost exclusively used for malignant
disease [63, 64]. The percutaneous treatment of biliary
lesions is frequently staged, requiring several sessions to
achieve therapeutic goals, though, in themajority of patients,
liver function indices improve following a single treatment
[62]. PBD can be associated with major complications
including sepsis, haemorrhage and localised infective and
inflammatory processes (abscess, peritonitis, cholecystitis,
and pancreatitis) [64]. The incidence of complications is
higher in the oncology than in the general population,
perhaps related to advanced malignancy and the potential
presence of coexisting immunosuppression [64, 65]. The
incidence of cholangitis in oncology patients undergoing
PBD approaches 50%, such infection observed twice as
commonly in those with internal and external drainage
than in those with external drainage alone [66]. The longer
the duration of PBD is the more likely the patient is to
develop cholangitis [67]. The incidence of infected bile in
patients with malignant biliary obstruction is 25% to 36%
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Figure 4: 21-year-old woman with cervical cancer develops ureteric obstruction due to local disease invasion. (a) Contrast injection
immediately following percutaneous nephrostomy confirms 8 french catheter in good position within renal collecting system. (b) Contrast-
enhanced CT scan confirms percutaneous nephrostomy catheter in positioned within left renal collecting system. Patient is post total
abdominal hysterectomy and bilateral salpingo-oophorectomy.
[68]. Prior to initiating percutaneous biliary procedures, all
patients should be administered appropriate prophylactic
antibiotics to minimise septic complications, including cover
for escherichia coli, klebsiella, enterococcus, streptococcus,
enterobacter and pseudomonas aeruginosa [8].
4.2. Renal Obstruction. Malignant ureteral obstruction is an
ominous sign in the cancer patient and may be due to
extrinsic tumor compression, retroperitoneal adenopathy,
or direct tumor invasion [69]. Ureteral obstruction can be
induced by a wide range of malignancies, most commonly
those of gastrointestinal, urologic, or gynaecologic origin,
and may be unilateral or bilateral. Management requires
urinary decompression, often by means of percutaneous
nephrostomy (PCN). PCN is the most common renal
intervention performed by IR and, by providing direct access
to the urinary tract, allows drainage of tract contents as well
as providing access for further uroradiologic intervention
via the route established [70]. Indications for PCN in the
emergent setting include urinary tract sepsis, pyonephrosis,
deteriorating renal function, or electrolyte disturbances such
as hyperkalemia and metabolic acidosis [8]. Potential ben-
efits of urinary decompression and diversion by this means
include reduction in the incidence of gram-negative septi-
caemia due to renal obstruction, partial recovery of renal
function, reversal of metabolic disturbance, and reduced
inpatient admission times. Image guidance may be provided
with fluoroscopy, ultrasound, or often a combination of
both modalities [71] (Figure 4). The size and type of the
drainage catheter should be chosen appropriately according
to the nature of the fluid to be drained [70]. In cases of
malignant ureteric obstruction, when retrograde stenting is
unsuccessful or not feasible, percutaneous dilatation of the
stricture may be achieved antegradely through the PCN tract
where, under fluoroscopic guidance, a catheter is manipu-
lated across the stenotic region and the lesion is progressively
dilated by catheter advancement, ureteral dilator, or by inflat-
ing balloons of appropriate diameter and length [70]. After
dilatation, an internal ureteral stent, or internal-external
nephroureteral catheter is placed to prevent restenosis [70,
72]. Plastic stents are favoured over metal ones because they
induce less urothelial hyperplasia and can be easily replaced.
In a series of 102 cases of malignant ureteral obstruction
(68% bilateral), initial management with PCN or ureteral
stent achieved successful decompression of the system in
95% of cases [73]. The rate of successful completion of PCN
in oncology is mainly determined by the degree of dilatation
of the collecting system and by the patient’s body habitus
[74]. However, in the above series, significant complications
such as infection and catheter blockage were observed in 53%
of patients and overall survival was poor with a median of
seven months [73]; these outcomes may appear on initial
reflection to be disappointing, but are most likely explained
by advanced stage of malignancy in most patients.
4.3. Upper Gastrointestinal Obstruction. Patients with head,
neck, or oesophageal malignant lesions are, due to lumi-
nal obstruction or swallow impairment, frequently unable
to tolerate adequate oral intake and require nutritional
support, often by gastrostomy or gastrojejunostomy [75].
The interventional radiologist can play an important role
in the provision of enteral alimentation to these patients
(Figure 5). Percutaneous image-guided placement of feeding
tubes has demonstrated higher technical success rates and is
considered safer than endoscopic or surgical placement [76].
In addition, it may be successfully performed in patients in
whom conventional endoscopy is impossible [75]. Among
the more common early complications of gastrostomy inser-
tion are infection and mild discomfort on feeding, which
have been observed in 23% and 33% of cases respectively [77,
78]. Tube dislodgement is relatively common; however, if the
tract is established for more than two weeks, it is frequently
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Figure 5: 73-year-old man with pancreatic cancer: percutaneous
gastrojejunostomy catheter placed for feeding. Contrast injection
following placement of percutaneous gastrojejunostomy tube con-
firms that the tip of the tube is in excellent position in the jejunum
(arrow). Note the gas-filled stomach (white arrow) and the locking
pigtail catheter in stomach which serves to maintain catheter in
position and prevent dislodgement.
possible to access the tract and reinsert the tube without
the need for repuncture of the stomach [8]. Complication
rates are similar with gastrostomy and gastrojejunostomy.
Malignant small bowel obstruction, as seen in patients
with peritoneal carcinomatosis, often of ovarian origin, is a
further indication for gastrostomy or gastrojejunostomy as a
means of decompression, with a technical success rate in the
region of 98% [79]. The presence of ascites in such patients
mandates paracentesis prior to procedure as peritoneal fluid
leads to technical diﬃculty and the risk of pericatheter
leakage and the possibility of peritonitis [80–82]. Gastropexy
is advised prior to gastrostomy to reduce the likelihood
of catheter dislodgement from the anterior abdominal wall
and to reduce risk of peritonitis and peri-catheter leakage
[8, 80, 82].
4.4. Pleural Space Intervention. Malignant pleural eﬀusions,
often related to pleural and lymphatic involvement, are a
significant source of morbidity in the oncology patient,
presenting with dyspnoea, cough, and chest pain [83]. As
a malignant pleural eﬀusion is a preterminal event with a
mean survival of three months, the usual aim of treatment
is palliation, and relief of symptoms and prevention of rec-
ollection [84, 85]. Successful drainage can be achieved by IR
with catheter placement under fluoroscopic, ultrasound or
CT guidance. Image-guided needle aspiration of pleural fluid
collections may also be performed to evaluate for the pres-
ence of malignant cells using cytology, thus aiding in the ini-
tial diagnosis of malignancy or staging of known disease [85].
Therapeutic thoracocentesis provides temporary symp-
tomatic relief until the eﬀusion reaccumulates, as is often
the case in the setting of malignant eﬀusions, necessitating
a repeat procedure. Definitive treatment requires pleurodesis
[86]. Prevention of recurrent pleural eﬀusions can be
achieved by chemical or talc pleurodesis. Prior to pleurodesis,
large eﬀusions require drainage to optimise success rates
of pleurodesis and to prevent accumulation of therapeutic
agents within the pleural space. Based on eﬃcacy and the
likelihood of recurrence, thoracoscopic pleurodesis is the
preferred technique but has the drawback of requirement
for a general anaesthetic [86]. IR pleurodesis, entailing
instillation of the sclerosing agent via a thoracostomy tube
once complete evacuation of the eﬀusion has occurred, can
be performed at the bedside and is generally well tolerated
[8]. Available evidence supports the need for chemical
sclerosants to achieve successful pleurodesis, with talc as
the agent of choice [86]. Other agents employed include
tetracycline, bleomycin, and mustine.
4.5. Pain. A significant source of cancer-related morbidity,
particularly in advanced disease, is pain. Prevalence can
range from 40% to as high as 90% with advanced disease
[87, 88], and when inadequately controlled, the impact of
pain can be profound. Opiates, with their considerable side
eﬀect profile, remain the mainstay of treatment and pain can
be well managed in 80% to 90% of cancer patients according
to the principles of the World Health Organisation (WHO)
analgesic ladder [89–91]. Patients who have pain that is not
controlled by these means, or who have well-controlled pain
but with intolerable analgesic side eﬀects, may benefit from
interventional pain management measures. As techniques
expand, IR is assuming an evolving role in the management
of cancer-associated pain. However, while IR has a role in
the treatment of oncological pain, it is noteworthy that
IR interventions may themselves be a source of significant
pain and discomfort among patients, particularly procedures
involving drainage of the renal and biliary tracts [92].
Optimal analgesia during and after such procedures is
essential. Percutaneous vertebroplasty, in recent years, has
emerged as an eﬀective minimally invasive treatment for
severe and refractory pain secondary to vertebral fracture
[93, 94]. In particular, its use has been met with considerable
success in the treatment of painful osteoporotic vertebral
compression fractures, where fracture stability is achieved by
introduction of cement. It has also found less frequent use
in the treatment of fractures secondary to neoplastic disease
[94, 95]. Osteolytic processes, such as myeloma, often induce
fractures, resulting in instability and pain. Vertebroplasty has
been shown to reduce requirements for analgesia and is now
being utilised in the treatment of vertebral fractures which
result from malignant osseous infiltration [95]. Again, the
complication risk is higher among oncology patients than in
the general population, with rates of 5% and 1%, respectively
for major complications [95]. The more significant com-
plications include leakage of cement into the spinal canal,
pulmonary embolus, and pulmonary oedema. The beneficial
eﬀects of pain reduction and improvedmobility are observed
in 50%–60%of oncology patients undergoing vertebroplasty,
with better results achieved by treating subacute rather than
chronic fractures [96].
Neuropathic pain associated with upper abdominal
visceral tumours is frequently poorly responsive to analgesic
therapy [97]. When resistant to analgesics, celiac ganglion
neurolysis and nerve block can achieve successful palliation
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of pain in the majority of patients, particularly that related
to pancreatic, gastric, oesophageal, and biliary malignancies
[97]. Agents employed include local alcohol and phenol,
which induce permanent nerve root destruction, and triam-
cinlone, which causes reversible nocireceptor blockade [98].
A variety of imaging modalities can be used to guide celiac
axis block; CT ismost commonly used with either an anterior
or posterior approach, dependent on operator experience
and anatomic considerations in the individual patient [99].
Reported minor complications include transient diarrhoea
in 73% and orthostatic hypotension in 12% [100].
4.6. Venous Thromboembolic Disease. Malignancy is an
established risk factor for venous thromboembolism. Fifteen
percent of cancer patients develop a symptomatic venous
thrombosis in the course of their therapy, and 50% have
evidence of venous thrombosis at autopsy [101]. Vena caval
filters, intravascular devices designed to prevent pulmonary
embolus by trapping venous emboli, are an accepted method
of managing venous thromboembolism in the oncology
patient. Indications for insertion include the occurrence
of a lower limb deep venous thrombosis in patients for
whom anticoagulation is contraindicated, in those in whom
a complication of anticoagulation has occurred, or in those
who develop recurrent PEs despite adequate anticoagulation
[102]. In experienced hands, the technical success rate of
inferior vena caval filter placement is over 97% [102].
Empirical use is not at present supported in the literature.
Recent developments in endovascular technologies have
provided radiologists with an assortment of minimally inva-
sive, catheter-based strategies to manage venous thrombus,
including both deep venous thromboses and pulmonary
emoboli. These percutaneous treatment methods for venous
thrombotic conditions include catheter-directed thrombol-
ysis, percutaneous mechanical thrombectomy devices, and
adjuvant venous angioplasty and stenting. Catheter-directed
thrombolysis therapy involves the use of infusion catheters
and wires to achieve local high-dose delivery of thrombolytic
agents to the thrombus with the aim of achieving more rapid
lysis. This allows a more predictable thrombolytic eﬀect with
a lower risk of haemorrhagic complications and with higher
patency rates than systemic thrombolysis, with the added
benefit of ability to visualise the entire venous system prior to
and after administration of the pharmacologic agent [103].
Percutaneous mechanical thrombectomy may be used as a
primary therapy for an acute thrombotic event, for thrombus
involving large vessels such as the vena cava, or, more
commonly, for patients in whom, despite conventional anti-
coagulation or catheter-directed therapy, there is persistent
thrombus. Such therapy also has a role in patients with
contraindications to continuous anti-coagulation or the use
of thrombolytic agents. It is however suggested that, in
the absence of contraindications to the use of thrombolytic
agents, mechanical thrombectomy devices should be used
in conjunction with pharmacological thrombolysis [103].
Mechanical, chemical, and hybrid pharmacomechanical
thrombectomy devices are available for clot extraction with
variable success rates [104], though further discussion of
these devices is outside the scope of this paper.
5. Conclusion
With the expanding application of minimally invasive tech-
niques to the investigation andmanagement of malignancies,
the interventional radiologist is assuming a more prominent
role in the multidisciplinary team that cares for the patient
with cancer. The use of IR techniques in oncology patients
should be evidence based to ensure optimal outcome and
minimise potential complications.
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